H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.

Original reporting
Published Oct 16, 2026, 12:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 1:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$AQST
Bullish
high confidence
Mentioned
$AQST
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AQSTBullishMed
01

Why it matters

Regulatory acknowledgment is a fresh catalyst that could drive short‑term buying, while the revenue beat provides a modest supportive backdrop.

02

Market read

The FDA resubmission acknowledgment is a primary, material event for AQST, offering a clear trading catalyst for the stock.

03

What to watch

Potential cash‑burn and debt load could constrain the company if approval is delayed.

Relevance 7/10Novelty 7/10Timing: today

Background

The article reports H.C. Wainwright's rating reiteration and summarizes recent FDA regulatory milestones for AQST's Anaphylm candidate, along with recent Q2 revenue results.

Company-level read

Ticker impact

$AQSTBullishHigh confidence
Context

H.C. Wainwright reiterated a Buy rating and $10 price target after the FDA completed the resubmission of AQST's New Drug Application for Anaphylm and set a PDUFA goal date of March 16, 2027.

Expected impact

likely upward pressure as investors price in the FDA's Class 2 response and upcoming decision date

Evidence & confidence

The FDA's acknowledgment of the resubmission is a primary disclosure for a micro‑cap biotech, indicating the drug remains on track and may attract additional buying.

Market effects

Positive signal for the allergy‑treatment biotech niche and may lift peer valuations.

U.S. biotech sector could see modest gains as FDA activity is highlighted.

Limited to investors focused on U.S. biotech pipelines.

Counterpoint

The drug still faces a lengthy review timeline and no guarantee of approval; the stock may be overbought on hype.

Key entities

  • Aquistive Therapeutics

    Biotech developing Anaphylm, a sublingual rescue medication for severe allergic reactions.

  • H.C. Wainwright

    Equity research firm that reiterated a Buy rating and $10 price target for AQST.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA Resubmission

Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a sublingual epinephrine film for severe allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The company addressed prior FDA concerns in the resubmission. If approved, Anaphylm could offer a needle-free treatment option. AQST stock closed at $4.61, up 1.30% in pre-market trading.